IL-17 and -23 Inhibitors for the Treatment of Psoriasis

Abstract

Psoriasis is a chronic inflammatory skin condition with a significant global burden of disease and a wide array of potential treatment options, ranging from topical to systemic therapies. There are currently 11 biologic agents approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe psoriasis. The emergence of IL-17 and IL-23 inhibitors has significantly improved the efficacy and safety of treatment options for patients with psoriasis. Given the number of potential therapies, a variety of factors may be considered in optimising a patient’s regimen, including efficacy, safety, cost, persistence rate, and discontinuation rate. The aim of this narrative review is to provide a concise yet comprehensive review of the biologic agents that inhibit IL-17 or IL-23 available for patients 18 years of age or older with moderate-to-severe psoriasis.